These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 3531342)
1. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate. Sher A; Hieny S; Joiner K J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342 [TBL] [Abstract][Full Text] [Related]
2. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Joiner K; Sher A; Gaither T; Hammer C Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6593-7. PubMed ID: 2944112 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody. Schenkman S; Güther ML; Yoshida N J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798 [TBL] [Abstract][Full Text] [Related]
4. Lytic rabbit IgG for tissue culture trypomastigotes of Trypanosoma cruzi alters the extent and form of complement deposition. Rimoldi MT; Tartanian A; Joiner KA Exp Parasitol; 1989 Feb; 68(2):160-7. PubMed ID: 2647504 [TBL] [Abstract][Full Text] [Related]
5. Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. Tomlinson S; Pontes de Carvalho LC; Vandekerckhove F; Nussenzweig V J Immunol; 1994 Oct; 153(7):3141-7. PubMed ID: 8089492 [TBL] [Abstract][Full Text] [Related]
6. Ligand-binding renders the 160 kDa Trypanosoma cruzi complement regulatory protein susceptible to proteolytic cleavage. Norris KA Microb Pathog; 1996 Oct; 21(4):235-48. PubMed ID: 8905613 [TBL] [Abstract][Full Text] [Related]
7. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. Norris KA; Bradt B; Cooper NR; So M J Immunol; 1991 Oct; 147(7):2240-7. PubMed ID: 1717552 [TBL] [Abstract][Full Text] [Related]
9. gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes. Joiner K; Hieny S; Kirchhoff LV; Sher A J Exp Med; 1985 May; 161(5):1196-212. PubMed ID: 3886827 [TBL] [Abstract][Full Text] [Related]
10. Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade. Krettli AU; Pontes de Carvalho LC Clin Exp Immunol; 1985 Nov; 62(2):270-7. PubMed ID: 3910312 [TBL] [Abstract][Full Text] [Related]
11. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Rimoldi MT; Sher A; Heiny S; Lituchy A; Hammer CH; Joiner K Proc Natl Acad Sci U S A; 1988 Jan; 85(1):193-7. PubMed ID: 3277170 [TBL] [Abstract][Full Text] [Related]
12. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65. Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193 [TBL] [Abstract][Full Text] [Related]
13. Proteins anchored via glycosylphosphatidylinositol and solubilizing phospholipases in Trypanosoma cruzi. de Almeida ML; Heise N Biol Res; 1993; 26(1-2):285-312. PubMed ID: 7670541 [TBL] [Abstract][Full Text] [Related]
14. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. Almeida IC; Milani SR; Gorin PA; Travassos LR J Immunol; 1991 Apr; 146(7):2394-400. PubMed ID: 1706399 [TBL] [Abstract][Full Text] [Related]
15. Binding of complement to trypomastigotes of a Brazil strain of Trypanosoma cruzi: evidence for heterogeneity within the strain. Jacobson KC; Washburn RG; Kuhn RE J Parasitol; 1992 Aug; 78(4):697-704. PubMed ID: 1635029 [TBL] [Abstract][Full Text] [Related]
16. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. Joiner KA; Warren KA; Tam M; Frank MM J Immunol; 1985 May; 134(5):3411-9. PubMed ID: 3920319 [TBL] [Abstract][Full Text] [Related]
18. Cryptic epitope explains the failure of a monoclonal antibody to bind to certain isolates of Trypanosoma cruzi. Kirchhoff LV; Hieny S; Shiver GM; Snary D; Sher A J Immunol; 1984 Nov; 133(5):2731-5. PubMed ID: 6207242 [TBL] [Abstract][Full Text] [Related]
19. Antibody to Trypanosoma cruzi neuraminidase enhances infection in vitro and identifies a subpopulation of trypomastigotes. Cavallesco R; Pereira ME J Immunol; 1988 Jan; 140(2):617-25. PubMed ID: 3121750 [TBL] [Abstract][Full Text] [Related]
20. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Kipnis TL; David JR; Alper CA; Sher A; da Silva WD Proc Natl Acad Sci U S A; 1981 Jan; 78(1):602-5. PubMed ID: 6454138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]